Pre-Open Stock Movers 11/10: (TUBE) (MNKD) (SODA) Higher; (HLIT) (ANTH) (NVAX) Lower (more...)

November 10, 2016 9:12 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Today's Pre-Open Stock Movers

TubeMogul (Nasdaq: TUBE) 82.5% HIGHER; Adobe (Nasdaq: ADBE) announced it has entered into a definitive agreement to acquire TubeMogul (Nasdaq: TUBE) for approximately $540 million net of debt and cash. Under the terms of the agreement, Adobe will commence a cash tender offer to acquire all of the outstanding common stock of TubeMogul for $14 per share.

EnteroMedics Inc. (NASDAQ: ETRM) 55% HIGHER; reports third quarter results.

MannKind Corporation (Nasdaq: MNKD) 21.2% HIGHER; announced that MannKind and Sanofi (NYSE: SNY) have entered into an agreement.

Harmonic (NASDAQ: HLIT) 19.1% LOWER; reported Q3 EPS of ($0.01), $0.04 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $101.4 million versus the consensus estimate of $107.24 million. GUIDANCE: Harmonic sees Q4 2016 EPS of $5.00-$0.07, versus the consensus of $0.13. Harmonic sees Q4 2016 revenue of $105.8-110.8 million, versus the consensus of $116.1 million.

Avid Technology (NASDAQ: AVID) 16.6% LOWER; reported Q3 EPS of $0.23, $0.19 worse than the analyst estimate of $0.42. Revenue for the quarter came in at $119 million versus the consensus estimate of $130.62 million. GUIDANCE: Avid Technology sees FY2016 revenue of $105-120 million, versus the consensus of $139.4 million. Avid Technology sees FY2016 revenue of $502-517 million, versus the consensus of $547.9 million.

SodaStream (NASDAQ: SODA) 16.5% HIGHER; reported Q3 EPS of $0.69, $0.46 better than the analyst estimate of $0.23. Revenue for the quarter came in at $124.2 million versus the consensus estimate of $115.05 million.

Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) 16.2% LOWER; announced that the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus erythematosus (SLE) failed to meet its primary endpoint based upon the SLE Responder Index-6 (SRI-6) at 52 weeks. Although 47% of patients in the blisibimod arm versus 42% of patients in the placebo arm achieved this endpoint, the difference was not statistically significant. The SRI is a composite index comprised of SELENA-SLEDAI, BILAG and Physician Global Assessment criteria. A SRI-6 response requires a decrease of at least 6 points in SELENA-SLEDAI. The magnitude of blisibimod treatment effects for other SLE Response (SRI-4, and SRI-8) also did not achieve statistical significance.

Trovagene (NASDAQ: TROV) 15.2% LOWER; reported Q3 EPS of ($0.34), $0.01 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $89 thousand versus the consensus estimate of $320 thousand.

Novavax (NASDAQ: NVAX) 12.9% LOWER; reported Q3 EPS of ($0.24), $0.02 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $4.02 million.

Rapid7, Inc. (NASDAQ: RPD) 10% LOWER; reported Q3 EPS of ($0.13), $0.07 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $40.3 million versus the consensus estimate of $39.42 million. GUIDANCE: Rapid7, Inc. sees Q4 2016 EPS of ($0.28)-($0.26), versus the consensus of ($0.24). Rapid7, Inc. sees Q4 2016 revenue of $42.2-43.6 million, versus the consensus of $43.3 million. Rapid7, Inc. sees FY2016 EPS of ($0.87)-($0.84), versus the consensus of ($0.91). Rapid7, Inc. sees FY2016 revenue of $154.6-156.0 million, versus the consensus of $154.7 million.

Shake Shack (NYSE: SHAK) 9.6% HIGHER; reported Q3 EPS of $0.15, $0.01 better than the analyst estimate of $0.14. Revenue for the quarter came in at $74.6 million versus the consensus estimate of $69.33 million. Same-Shack sales increased 2.9%. GUIDANCE: Shake Shack sees FY2016 revenue of $264-265 million, versus the consensus of $258.55 million. Shake Shack sees FY2016 revenue of $348-352 million, versus the consensus of $335.4 million.

Kohl's Corp. (NYSE: KSS) 8.3% HIGHER; reported Q3 EPS of $0.80, $0.10 better than the analyst estimate of $0.70. Revenue for the quarter came in at $4.33 billion versus the consensus estimate of $4.33 billion. Comparable store sales fell 1.7% GUIDANCE: Kohl's Corp. sees FY2016 EPS of $3.80-$4.00, versus the consensus of $3.87.

Omeros (NASDAQ: OMER) 8.1% HIGHER; reported Q3 EPS of ($0.34), $0.06 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $11.64 million.

TASER Int'l (NASDAQ: TASR) 8.1% HIGHER; reported Q3 EPS of $0.07, $0.01 better than the analyst estimate of $0.06. Revenue for the quarter came in at $71.9 million versus the consensus estimate of $59 million. TASER also announced today that following a transition period, CFO Dan Behrendt will be leaving the Company to pursue other opportunities.

CSRA, Inc. (NYSE: CSRA) 7.7% HIGHER; reported Q2 EPS of $0.56, $0.10 better than the analyst estimate of $0.46. Revenue for the quarter came in at $1.26 billion versus the consensus estimate of $1.24 billion.

ZELTIQ Aesthetics (NASDAQ: ZLTQ) 7.6% HIGHER; reported Q3 EPS of $0.12, $0.04 better than the analyst estimate of $0.08. Revenue for the quarter came in at $95.2 million versus the consensus estimate of $90.56 million. On a non-GAAP basis, the company reported adjusted EBITDA of $16.6 million, or 17.4% of revenue, for the third quarter 2016, compared to $5.6 million, or 9.2% of revenue, for the third quarter 2015. GUIDANCE: ZELTIQ Aesthetics sees FY2016 revenue of $352-352 million, versus prior guidance of $340-350 million.

Freeport-McMoRan (NYSE: FCX) 6.4% HIGHER; gains on copper rally on Trump.

Bovie Medical Corporation (NYST: BVX) 5.8% LOWER announced today that the Company and certain selling stockholders intend to offer shares of the Companys common stock in concurrent public offerings. Bovie Medical and the selling stockholders also expect to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. Bovie Medical will use the net proceeds from the offering to expand its sales and marketing activities, to expand its research and development efforts, to conduct clinical trials, and for general corporate purposes and working capital. The Company will not receive any proceeds from the sale of common stock by the selling stockholders.

SolarEdge Technologies (NASDAQ: SEDG) 5% LOWER; reported Q1 EPS of $0.46, $0.02 better than the analyst estimate of $0.44. Revenue for the quarter came in at $128.5 million versus the consensus estimate of $132.28 million. GUIDANCE: SolarEdge Technologies sees Q2 2017 revenue of $110-120 million, versus the consensus of $136.91 million.

Merrimack Pharma (NASDAQ: MACK) 5.3% LOWER; reported Q3 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $28.07 million versus the consensus estimate of $39.2 million.

Macy's (NYSE: M) 4% HIGHER; reported Q3 EPS of $0.46, $0.05 better than the analyst estimate of $0.41. Revenue for the quarter came in at $5.63 billion versus the consensus estimate of $5.65 billion. Comps fell 2.7 percent, versus a drop of 3.4 percent expected.

U.S. Silica Holdings, Inc. (NYSE: SLCA) 4% LOWER; announced that it has commenced an underwritten public offering of 9,000,000 shares of U.S. Silica common stock.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Pre-Open Losers, Pre-Open Winners, Definitive Agreement, Pre Market Movers

Add Your Comment